| 000 | 01283 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250513154020.0 | ||
| 264 | 0 | _c19990107 | |
| 008 | 199901s 0 0 eng d | ||
| 022 | _a1358-863X | ||
| 024 | 7 |
_a10.1177/1358836X9800300202 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHawari, F I | |
| 245 | 0 | 0 |
_aHeparin attenuates norepinephrine-induced venoconstriction. _h[electronic resource] |
| 260 |
_bVascular medicine (London, England) _c1998 |
||
| 300 |
_a95-100 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGuanylate Cyclase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aHeparin _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylene Blue _xpharmacology |
| 650 | 0 | 4 |
_aNorepinephrine _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVasodilator Agents _xpharmacology |
| 700 | 1 | _aShykoff, B E | |
| 700 | 1 | _aIzzo, J L | |
| 773 | 0 |
_tVascular medicine (London, England) _gvol. 3 _gno. 2 _gp. 95-100 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1358836X9800300202 _zAvailable from publisher's website |
| 999 |
_c9760525 _d9760525 |
||